CY1122208T1 - Μεθοδος μετρονομικης χορηγησης προφαρμακων καπτοθεκινης (π.χ. peg-ιρινοτεκανης) - Google Patents
Μεθοδος μετρονομικης χορηγησης προφαρμακων καπτοθεκινης (π.χ. peg-ιρινοτεκανης)Info
- Publication number
- CY1122208T1 CY1122208T1 CY20191100970T CY191100970T CY1122208T1 CY 1122208 T1 CY1122208 T1 CY 1122208T1 CY 20191100970 T CY20191100970 T CY 20191100970T CY 191100970 T CY191100970 T CY 191100970T CY 1122208 T1 CY1122208 T1 CY 1122208T1
- Authority
- CY
- Cyprus
- Prior art keywords
- captothekin
- irinotecan
- prodrugs
- peg
- metronomic administration
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 229960004768 irinotecan Drugs 0.000 title 1
- 229940002612 prodrug Drugs 0.000 title 1
- 239000000651 prodrug Substances 0.000 title 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 150000003384 small molecules Chemical class 0.000 abstract 1
- 230000002459 sustained effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9951608P | 2008-09-23 | 2008-09-23 | |
| US10693108P | 2008-10-20 | 2008-10-20 | |
| US17343309P | 2009-04-28 | 2009-04-28 | |
| PCT/US2009/005284 WO2010036335A1 (en) | 2008-09-23 | 2009-09-23 | Compositions and methods for achieving sustained therapeutic drug concentrations in a subject |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1122208T1 true CY1122208T1 (el) | 2020-11-25 |
Family
ID=41268391
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20191100970T CY1122208T1 (el) | 2008-09-23 | 2019-09-17 | Μεθοδος μετρονομικης χορηγησης προφαρμακων καπτοθεκινης (π.χ. peg-ιρινοτεκανης) |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US8906353B2 (enExample) |
| EP (1) | EP2349346B1 (enExample) |
| JP (3) | JP2012503602A (enExample) |
| KR (1) | KR20110063457A (enExample) |
| CN (1) | CN102164617A (enExample) |
| AU (1) | AU2009297091B2 (enExample) |
| CA (1) | CA2736939C (enExample) |
| CY (1) | CY1122208T1 (enExample) |
| DK (1) | DK2349346T3 (enExample) |
| ES (1) | ES2744975T3 (enExample) |
| HR (1) | HRP20192120T1 (enExample) |
| HU (1) | HUE047352T2 (enExample) |
| IL (1) | IL211888A (enExample) |
| LT (1) | LT2349346T (enExample) |
| MX (1) | MX2011003063A (enExample) |
| PL (1) | PL2349346T3 (enExample) |
| PT (1) | PT2349346T (enExample) |
| RS (1) | RS59607B1 (enExample) |
| SI (1) | SI2349346T1 (enExample) |
| SM (1) | SMT201900609T1 (enExample) |
| WO (1) | WO2010036335A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2011003063A (es) | 2008-09-23 | 2011-04-21 | Nektar Therapeutics | Composiciones y metodos para lograr concentraciones terapeuticas de farmaco sostenidas en un individuo. |
| US9359376B2 (en) * | 2011-04-08 | 2016-06-07 | Sphaera Pharma Pte. Ltd | Substituted methylformyl reagents and method of using same to modify physicochemical and/or pharmacokinetic properties of compounds |
| CN104813167B (zh) * | 2012-11-28 | 2019-04-09 | 尼克塔治疗公司 | 用于评估和预测用一种长效拓扑异构酶i抑制剂进行乳腺癌治疗的疗效的方法 |
| EP3258913A1 (en) * | 2015-02-17 | 2017-12-27 | Mallinckrodt Nuclear Medicine LLC | Modified docetaxel liposome formulations and uses thereof |
| AU2017273495B2 (en) | 2016-06-02 | 2023-01-12 | Innopharmax, Inc. | Metronomic oral gemcitabine for cancer therapy |
| CN106539557A (zh) * | 2016-10-08 | 2017-03-29 | 西安交通大学 | 一种基于恒速静脉输入的药代动力学参数的测定方法 |
| EP3852793B1 (en) | 2018-09-17 | 2025-11-19 | The Children's Hospital Of Philadelphia | Macromolecular prodrug peg-[sn22]4 |
| AU2022226605A1 (en) * | 2021-02-23 | 2023-10-12 | Edison Oncology | Compositions and methods to improve the therapeutic benefit of suboptimally administered compounds and therapies for the treatment of diseases |
| CN115317486B (zh) * | 2022-08-17 | 2024-04-19 | 南昌大学 | 一种共载紫杉醇和伊立替康前药纳米制剂及其制备方法 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4406793A (en) | 1992-06-04 | 1993-12-30 | Clover Consolidated, Limited | Water-soluble polymeric carriers for drug delivery |
| US5614549A (en) | 1992-08-21 | 1997-03-25 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
| US5965566A (en) | 1993-10-20 | 1999-10-12 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
| US5840900A (en) | 1993-10-20 | 1998-11-24 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
| US5880131A (en) | 1993-10-20 | 1999-03-09 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
| US5919455A (en) | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5605976A (en) | 1995-05-15 | 1997-02-25 | Enzon, Inc. | Method of preparing polyalkylene oxide carboxylic acids |
| IL117684A (en) | 1995-04-07 | 2002-02-10 | Pharmacia & Upjohn Inc | Intermediates and Process for Production of History of Kempotocin (CPT-11) and Related Compounds |
| US5726181A (en) | 1995-06-05 | 1998-03-10 | Bionumerik Pharmaceuticals, Inc. | Formulations and compositions of poorly water soluble camptothecin derivatives |
| SG50747A1 (en) | 1995-08-02 | 1998-07-20 | Tanabe Seiyaku Co | Comptothecin derivatives |
| PL189698B1 (pl) | 1996-03-12 | 2005-09-30 | Pg Txl Co | Kompozycja farmaceutyczna zawierająca lek przeciwnowotworowy i jej zastosowania |
| US6011042A (en) | 1997-10-10 | 2000-01-04 | Enzon, Inc. | Acyl polymeric derivatives of aromatic hydroxyl-containing compounds |
| US6111107A (en) | 1997-11-20 | 2000-08-29 | Enzon, Inc. | High yield method for stereoselective acylation of tertiary alcohols |
| US6153655A (en) | 1998-04-17 | 2000-11-28 | Enzon, Inc. | Terminally-branched polymeric linkers and polymeric conjugates containing the same |
| JP2002542304A (ja) | 1999-04-28 | 2002-12-10 | ベクトレイムド インコーポレイテッド | 酵素的に活性化された重合薬物接合体 |
| AU4564200A (en) | 1999-04-29 | 2000-11-17 | Aventis Pharma S.A. | Method for treating cancer using camptothecin derivatives and 5-fluorouracil |
| CA2394980C (en) | 1999-12-22 | 2008-05-13 | Shearwater Corporation | Sterically hindered derivatives of water soluble polymers |
| WO2001062299A2 (en) | 2000-02-28 | 2001-08-30 | Shearwater Corporation | Water-soluble polymer conjugates of artelinic acid |
| US6629995B1 (en) | 2000-03-31 | 2003-10-07 | Super Gen, Inc. | Camptothecin conjugates |
| DK1301810T3 (da) | 2000-07-21 | 2009-01-26 | Schlumberger Services Petrol | Kernemagnetiske resonansfremgangsmåder til at uddrage information om et fluidum i en klippe |
| US20020182172A1 (en) | 2000-11-30 | 2002-12-05 | Shearwater Corporation | Water-soluble polymer conjugates of triazine derivatives |
| TWI246524B (en) | 2001-01-19 | 2006-01-01 | Shearwater Corp | Multi-arm block copolymers as drug delivery vehicles |
| US7401013B2 (en) | 2001-10-15 | 2008-07-15 | Lockheed Martin Corporation | Method to optimize test data |
| KR20050040832A (ko) | 2001-10-29 | 2005-05-03 | 넥타르 테라퓨틱스 에이엘, 코포레이션 | 단백질 키나아제 ｃ 억제제의 중합체 공액 |
| DE60219677T2 (de) | 2001-10-30 | 2008-05-15 | Nektar Therapeutics Al, Corp., Huntsville | Wasserlösliche polymerkonjugate von retinoesäure |
| AU2002346686A1 (en) * | 2001-12-07 | 2003-06-23 | Intermune, Inc. | Compositions and method for treating hepatitis virus infection |
| US6608076B1 (en) | 2002-05-16 | 2003-08-19 | Enzon, Inc. | Camptothecin derivatives and polymeric conjugates thereof |
| JP2005529938A (ja) | 2002-06-06 | 2005-10-06 | ユニバーシティ オブ ワシントン | 癌の発症を予防または遅延するためのアルテミシニン様化合物を使用する方法 |
| US7122189B2 (en) | 2002-08-13 | 2006-10-17 | Enzon, Inc. | Releasable polymeric conjugates based on aliphatic biodegradable linkers |
| KR20140070676A (ko) | 2002-09-06 | 2014-06-10 | 인설트 테라페틱스, 인코퍼레이티드 | 공유결합된 치료제 전달을 위한 사이클로덱스트린-기초 중합체 |
| CN1852740B (zh) | 2003-09-17 | 2011-05-11 | 耐科塔医药公司 | 多支链聚合物的药物前体 |
| US8394365B2 (en) | 2003-09-17 | 2013-03-12 | Nektar Therapeutics | Multi-arm polymer prodrugs |
| US7462627B2 (en) * | 2006-02-09 | 2008-12-09 | Enzon Pharmaceuticals, Inc. | Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers |
| EP1989212B1 (en) | 2006-02-17 | 2013-06-19 | Cascade Prodrug Inc. | Treatment of hyperproliferative diseases with vinca alkaloid n-oxide and analogs |
| MX2009008549A (es) | 2007-02-09 | 2009-08-18 | Enzon Pharmaceuticals Inc | Tratamiento de canceres resistentes o refractarios con conjugados polimericos de brazos multiples de 7-etil-10-hidroxicamptotecina. |
| CN101199857B (zh) | 2007-12-12 | 2011-04-13 | 中国药科大学 | mPEG-PLA-喜树碱类药物的结合物 |
| MX2011003063A (es) | 2008-09-23 | 2011-04-21 | Nektar Therapeutics | Composiciones y metodos para lograr concentraciones terapeuticas de farmaco sostenidas en un individuo. |
-
2009
- 2009-09-23 MX MX2011003063A patent/MX2011003063A/es active IP Right Grant
- 2009-09-23 PT PT97893648T patent/PT2349346T/pt unknown
- 2009-09-23 KR KR1020117005982A patent/KR20110063457A/ko not_active Ceased
- 2009-09-23 JP JP2011527834A patent/JP2012503602A/ja not_active Withdrawn
- 2009-09-23 SI SI200932010T patent/SI2349346T1/sl unknown
- 2009-09-23 DK DK09789364.8T patent/DK2349346T3/da active
- 2009-09-23 AU AU2009297091A patent/AU2009297091B2/en active Active
- 2009-09-23 US US13/120,551 patent/US8906353B2/en active Active
- 2009-09-23 CA CA2736939A patent/CA2736939C/en active Active
- 2009-09-23 HR HRP20192120TT patent/HRP20192120T1/hr unknown
- 2009-09-23 EP EP09789364.8A patent/EP2349346B1/en active Active
- 2009-09-23 RS RS20191501A patent/RS59607B1/sr unknown
- 2009-09-23 HU HUE09789364A patent/HUE047352T2/hu unknown
- 2009-09-23 WO PCT/US2009/005284 patent/WO2010036335A1/en not_active Ceased
- 2009-09-23 SM SM20190609T patent/SMT201900609T1/it unknown
- 2009-09-23 CN CN2009801371326A patent/CN102164617A/zh active Pending
- 2009-09-23 ES ES09789364T patent/ES2744975T3/es active Active
- 2009-09-23 LT LTEP09789364.8T patent/LT2349346T/lt unknown
- 2009-09-23 PL PL09789364T patent/PL2349346T3/pl unknown
-
2011
- 2011-03-23 IL IL211888A patent/IL211888A/en active IP Right Grant
-
2014
- 2014-11-17 JP JP2014232556A patent/JP6076317B2/ja active Active
- 2014-11-26 US US14/555,440 patent/US9801873B2/en active Active
-
2016
- 2016-09-26 JP JP2016186670A patent/JP2016216510A/ja not_active Withdrawn
-
2017
- 2017-10-03 US US15/723,981 patent/US10525051B2/en active Active
-
2019
- 2019-09-17 CY CY20191100970T patent/CY1122208T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2015034180A (ja) | 2015-02-19 |
| SMT201900609T1 (it) | 2020-01-14 |
| IL211888A0 (en) | 2011-06-30 |
| MX2011003063A (es) | 2011-04-21 |
| PL2349346T3 (pl) | 2020-03-31 |
| IL211888A (en) | 2015-08-31 |
| US20150087668A1 (en) | 2015-03-26 |
| CA2736939C (en) | 2021-09-14 |
| SI2349346T1 (sl) | 2019-12-31 |
| US20180028525A1 (en) | 2018-02-01 |
| AU2009297091B2 (en) | 2015-03-05 |
| KR20110063457A (ko) | 2011-06-10 |
| AU2009297091A1 (en) | 2010-04-01 |
| JP2012503602A (ja) | 2012-02-09 |
| PT2349346T (pt) | 2019-10-24 |
| JP2016216510A (ja) | 2016-12-22 |
| CA2736939A1 (en) | 2010-04-01 |
| DK2349346T3 (da) | 2019-10-07 |
| JP6076317B2 (ja) | 2017-02-08 |
| US8906353B2 (en) | 2014-12-09 |
| EP2349346B1 (en) | 2019-08-28 |
| US9801873B2 (en) | 2017-10-31 |
| HRP20192120T1 (hr) | 2020-02-21 |
| US20110269789A1 (en) | 2011-11-03 |
| LT2349346T (lt) | 2019-09-25 |
| CN102164617A (zh) | 2011-08-24 |
| RS59607B1 (sr) | 2020-01-31 |
| US10525051B2 (en) | 2020-01-07 |
| EP2349346A1 (en) | 2011-08-03 |
| HUE047352T2 (hu) | 2020-04-28 |
| WO2010036335A1 (en) | 2010-04-01 |
| ES2744975T3 (es) | 2020-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1119059T1 (el) | Χρηση προφαρμακων κανναβιδιολης σε τοπικη και διαδερμικη χορηγηση με μικροβελονες | |
| CY1126136T1 (el) | Μεθοδοι θεραπειας της αρθριτιδας | |
| CY1122687T1 (el) | Συνθεσεις και μεθοδοι για την τροποποιηση της smn2 συναρμογης σε ενα υποκειμενο | |
| SV2010003451A (es) | Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas | |
| MX376937B (es) | Metodos para tratar cancer pancreático mediante el uso de terapias de combinacion que comprenden irinotecano liposómico. | |
| CY1112831T1 (el) | Παραγωγα αζαβιρηενυlαμινοβενζοιc acid σαν παραγοντες καταστολης dhodh | |
| UY31543A1 (es) | Sistema de administracion de rnai de interferencia y usos del mismo | |
| AR088267A1 (es) | Derivados, de los factores de coagulacion sanguinea vii y viia, conjugados y complejos que comprenden a los mismos y sus usos | |
| BR112013004698A2 (pt) | composições farmacêuticas compreendendo derivados de poh | |
| CY1124890T1 (el) | Συστηματα και μεθοδοι χορηγησης φαρμακων για θεραπεια καρκινου της ουροδοχου κυστης που περιλαμβανουν οξαλιπλατινη | |
| EA201170592A1 (ru) | Комбинированная терапия с применением пептид эпоксикетонов | |
| CR20120625A (es) | Métodos de tratamiento contra el cáncer pancreático | |
| ME01814B (me) | Citotoksični agensi koji sadrže nove derivate tomaimicina i njihova terapeutska primjena | |
| GT200500155A (es) | Terapia del càncer resistente al platino | |
| DK3248600T3 (da) | Kombinationer og måder til administration af terapeutiske stoffer og kombinationsterapi | |
| UY28923A1 (es) | Compuestos terapéuticos: piridina como estructura base | |
| CR11065A (es) | Administracion semanal de inhibidores de peptidasa de dipeptidilo | |
| PH12014500386A1 (en) | Combination treatment for hepatitis c | |
| CY1118032T1 (el) | Διεργασιες για την εμπορικη παρασκευη φαρμακευτικα δραστικου παραγοντα | |
| CR20130530A (es) | Derivados glucósidos y sus usos para el tratamiento de la diabetes | |
| EA201391689A1 (ru) | Система доставки лекарственного средства | |
| MX2013012206A (es) | Metodo para producir substancias con gas sobresaturado,dispositivo de suministro transdermico de las mismas, y usos de las mismas. | |
| MX2013008175A (es) | Composiciones farmacéuticas para suministro tópico de fotosensibilizadores y usos de los mismos. | |
| UY31839A (es) | Compuestos | |
| MX337464B (es) | Profarmacos lipofilicos labiles al acido de los agentes quimioterapeuticos contra el cancer. |